Understanding Clopidogrel's Interaction with CYP2C19 Inhibitors
| Autor: | Amy Schueler, Matthew Price |
|---|---|
| Rok vydání: | 2010 |
| Předmět: |
Advanced and Specialized Nursing
Drug medicine.medical_specialty Acute coronary syndrome business.industry Vascular disease media_common.quotation_subject medicine.medical_treatment CYP2C19 medicine.disease Clopidogrel Coronary artery disease Angioplasty medicine In patient cardiovascular diseases Medical emergency business Intensive care medicine circulatory and respiratory physiology medicine.drug media_common |
| Zdroj: | The Journal for Nurse Practitioners. 6:715-720 |
| ISSN: | 1555-4155 |
| DOI: | 10.1016/j.nurpra.2010.08.014 |
| Popis: | Clopidogrel has established efficacy in the treatment and prevention of acute coronary syndrome, coronary artery disease, and peripheral vascular disease. A recent warning issued by the FDA regarding interactions between clopidogrel and certain commonly prescribed medications has important implications in the management of patients' pharmacotherapeutic regimens. This article offers an evidence-based review of clopidogrel pharmacology to better understand the FDA warning. Additionally, the article provides a nurse practitioner-derived action plan for identifying and addressing potential drug interactions in patients, with the goals of maintaining clopidogrel efficacy and adequately managing other comorbid conditions. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect